L&C Bio Co., Ltd

KOSDAQ 290650.KQ

L&C Bio Co., Ltd Total Non-Current Liabilities for the year ending December 31, 2023: USD 2.72 M

L&C Bio Co., Ltd Total Non-Current Liabilities is USD 2.72 M for the year ending December 31, 2023, a -95.30% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

L&C Bio Co., Ltd Total Non-Current Liabilities for the year ending December 31, 2022 was USD 57.80 M, a 712.37% change year over year.
L&C Bio Co., Ltd Total Non-Current Liabilities for the year ending December 31, 2021 was USD 7.12 M, a -50.47% change year over year.
L&C Bio Co., Ltd Total Non-Current Liabilities for the year ending December 31, 2020 was USD 14.36 M, a 552.33% change year over year.
L&C Bio Co., Ltd Total Non-Current Liabilities for the year ending December 31, 2019 was USD 2.20 M, a 62.14% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

KOSDAQ: 290650.KQ

L&C Bio Co., Ltd

CEO	Mr. Chul Lee Whan
IPO Date	Nov. 1, 2018
Location	South Korea
Headquarters	Suntechcity
Employees	122
Sector	Health Care
Industries Biotechnology Cosmetics Pharmaceuticals Research & Consulting

Description

L&C BIO Co., Ltd. operates as a research and development company in tissue regeneration medicine. It offers human tissue, medical device, and cosmetics products. The company was founded in 2011 and is headquartered in Seongnam, South Korea.

Key trends

Past 5 years